Revenue for Vertex Pharmaceuticals (VRTX)
According to Vertex Pharmaceuticals's latest reported financial statements, the company's current revenue (TTM) is $12.04B USD. Revenue is the total income from selling goods or services before any expenses. Unlike net income (earnings), revenue does not subtract operating costs, taxes, or other charges. Figures are in USD; chart and tables below use historical filings (not a live revenue-per-second estimate).
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingRevenueSwitch metric
TTM (last 4 quarters)
$12.04B
YoY change
+9.6%
5Y CAGR
+14.2%
Peak year (2025)
$12.07B
Cumulative revenue
$74.66B
Revenue history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
Revenue history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
| Fiscal year | Period ended | Reported | Revenue | YoY |
|---|---|---|---|---|
| 2025 | $12.07B | +9.6% | ||
| 2024 | $11.02B | +11.7% | ||
| 2023 | $9.87B | +10.5% | ||
| 2022 | $8.93B | +17.9% | ||
| 2021 | $7.57B | +22.1% | ||
| 2020 | $6.21B | +49.1% | ||
| 2019 | $4.16B | +36.6% | ||
| 2018 | $3.05B | +22.5% | ||
| 2017 | $2.49B | +46.2% | ||
| 2016 | $1.70B | +64.9% | ||
| 2015 | $1.03B | +77.9% | ||
| 2014 | $580.41M | -52.1% | ||
| 2013 | $1.21B | -20.6% | ||
| 2012 | $1.53B | +8.3% | ||
| 2011 | $1.41B | +883.9% | ||
| 2010 | $143.37M | +40.5% | ||
| 2009 | $102.05M | -41.9% | ||
| 2008 | $175.50M | -11.8% | ||
| 2007 | $199.01M | -8.0% | ||
| 2006 | $216.36M | +34.5% | ||
| 2005 | $160.89M | +56.6% | ||
| 2004 | $102.72M | +48.6% | ||
| 2003 | $69.14M | -57.1% | ||
| 2002 | $161.09M | -3.8% | ||
| 2001 | $167.49M | +114.4% | ||
| 2000 | $78.13M | +26.8% | ||
| 1999 | $61.60M | +38.7% | ||
| 1998 | $44.40M | +1.4% | ||
| 1997 | $43.80M | +229.3% | ||
| 1996 | $13.30M | -39.8% | ||
| 1995 | $22.10M | +12.8% | ||
| 1994 | $19.60M | -29.7% | ||
| 1993 | $27.90M | +634.2% | ||
| 1992 | $3.80M | +18.8% | ||
| 1991 | $3.20M | +39.1% | ||
| 1990 | $2.30M | — |
Revenue values are taken from Vertex Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Vertex Pharmaceuticals (VRTX) reported revenue of $12.07B – grew 9.6% year-over-year.
Through 2020–2025 (5 years), Vertex Pharmaceuticals revenue delivered a +14.2% annualised rate; sustaining 11 straight years of year-over-year growth.
$12.07B stands as the all-time-high annual revenue, posted in 2025, against a low of $2.30M during 1990.
Among 8 Healthcare peers, Vertex Pharmaceuticals (VRTX) ranks 9th; the peer median for revenue is $65.09B.
Vertex Pharmaceuticals Revenue by Year
Vertex Pharmaceuticals Revenue 2025: $12.07B
Vertex Pharmaceuticals revenue in 2025 was $12.07B, grew 9.6% from 2024. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Revenue 2024: $11.02B
Vertex Pharmaceuticals revenue in 2024 was $11.02B, grew 11.7% from 2023.
Vertex Pharmaceuticals Revenue 2023: $9.87B
Vertex Pharmaceuticals revenue in 2023 was $9.87B, grew 10.5% from 2022.
Vertex Pharmaceuticals Revenue 2022: $8.93B
Vertex Pharmaceuticals revenue in 2022 was $8.93B, grew 17.9% from 2021.
Vertex Pharmaceuticals Revenue 2021: $7.57B
Vertex Pharmaceuticals revenue in 2021 was $7.57B.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers — Revenue
Companies in the same sector as Vertex Pharmaceuticals, ranked by their latest revenue.
| Company | Revenue | Sector |
|---|---|---|
| UnitedHealth Group Incorporated (UNH) | $447.57B | Healthcare |
| Novo Nordisk A/S (NVO) | $309.06B | Healthcare |
| Johnson & Johnson (JNJ) | $94.19B | Healthcare |
| Eli Lilly and Company (LLY) | $65.18B | Healthcare |
| Merck & Co., Inc. (MRK) | $65.01B | Healthcare |
| AbbVie Inc. (ABBV) | $61.16B | Healthcare |
| AstraZeneca PLC (AZN) | $58.74B | Healthcare |
| Amgen Inc. (AMGN) | $36.74B | Healthcare |
Frequently asked questions
What is Vertex Pharmaceuticals's revenue?
- Latest reported revenue for Vertex Pharmaceuticals (VRTX) is $12.04B (period ending December 31, 2025).
How has Vertex Pharmaceuticals revenue changed year-over-year?
- Vertex Pharmaceuticals (VRTX) revenue changed +9.6% year-over-year on the latest annual filing.
What is the long-term growth rate of Vertex Pharmaceuticals revenue?
- Vertex Pharmaceuticals (VRTX) revenue compound annual growth rate is +14.2% over the most recent 5 years available.
When did Vertex Pharmaceuticals revenue hit its highest annual value?
- Vertex Pharmaceuticals revenue reached its highest annual value of $12.07B in 2025.
What was Vertex Pharmaceuticals revenue in 2024?
- Vertex Pharmaceuticals (VRTX) revenue in 2024 was $11.02B.
What was Vertex Pharmaceuticals revenue in 2025?
- Vertex Pharmaceuticals (VRTX) revenue in 2025 was $12.07B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
VRTX Overview
Company profile, financial tools, and key metrics
VRTX Revenue Counter
Earns $381.74 every second. See per minute, hour, and day.
VRTX Earnings Counter
Earns $125.36 per second net profit. See per minute, hour, and day.
VRTX Economic Scale
Exceeds Somalia, Fed. Rep.'s GDP. Compare with world economies.
VRTX What If Invested
What if you had invested $1,000? See historical returns from any date.
VRTX How It Makes Money
Discover visual breakdown of $12.04B in revenue — where it comes from and where it goes.
VRTX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
VRTX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
VRTX Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
VRTX Buybacks
1.75% TTM buyback yield. Shareholder yield & SBC comparison.
VRTX Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.